Horizon Pharma Q3 Loss Narrows - Quick Facts

(RTTNews) - Horizon Pharma Inc. (HZNP) reported that its third-quarter net loss narrowed to $5.5 million or $0.08 per share, from $17.0 million, or $0.47 per share last year.

Non-GAAP net loss for the quarter was $2.1 million, or $0.03 per share, compared to a non-GAAP net loss of $13.9 million or $0.39 per share in the prior year.

Net sales for the quarter were $26.2 million, compared to $6.5 million last year.

Analysts polled by Thomson Reuters expected the company to report a loss of $0.25 per share and revenues of $18.31 million. Analysts' estimates typically exclude special items.

DUEXIS gross and net sales during the third quarter of 2013 were $28.5 million and $23.5 million, respectively, after deducting sales discounts and allowances of $1.1 million and co-pay assistance costs of $3.9 million, compared to DUEXIS gross and net sales of $3.0 million and $2.6 million, respectively, during the third quarter of 2012.

The increase in DUEXIS sales during the third quarter of 2013 compared to the prior year quarter was primarily the result of the Company's expanded sales force in addition to product price increases implemented during the course of 2013.